title: Regimens for Cirrhotic Patients.
abstract: Therapy for hepatitis C has entered the era of all-oral direct-acting antiviral agents. Sustained response rates are now greater than 90% for all genotypes, although patients with cirrhosis remain the most difficult to treat. There are limited data for patients with cirrhosis and with hepatitis C genotypes 4 and 6 with cirrhosis. Genotype 3 patients with cirrhosis need additional strategies to achieve the sustained virologic response rates seen in genotype 1 patients with cirrhosis. This article outlines the currently available therapies for patients with cirrhosis and hepatitis C across all genotypes, with suggested management strategies.
authors.affiliation: Gastroenterology/Hepatology Division, Liver Transplantation, Indiana University Health, Indiana University School of Medicine, 975 West Walnut, IB 327, Indianapolis, IN 46202-5121, USA. Electronic address: pkwo@iu.edu.
authors.forename: Paul Y
authors.initials: PY
authors.lastname: Kwo
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000473:pathology / Q000821:virology*; D019384:Nucleic Acid Synthesis Inhibitors / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use; D012367:RNA, Viral / Q000096:biosynthesis; D019233:Retreatment; D017211:Treatment Failure; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors; D012324:RNA-Dependent RNA Polymerase
chemical_list: D000998:Antiviral Agents; D019384:Nucleic Acid Synthesis Inhibitors; D011480:Protease Inhibitors; D012367:RNA, Viral; D017361:Viral Nonstructural Proteins; C087036:NS-5 protein, hepatitis C virus; D012324:RNA-Dependent RNA Polymerase
keywords: Cirrhosis; Direct-acting antivirals; Hepatitis C; Ledipasvir; Ombitasvir; Paritaprevir; Simeprevir; Sofosbuvir